C2orf42: A Potential Cancer Therapeutic? (G54980)

Target Name: C2orf42

NCBI ID: G54980

C2orf42

Other Name(s): chromosome 2 open reading frame 42 | Chromosome 2 open reading frame 42, transcript variant 2 | Uncharacterized protein C2orf42 | C2orf42 variant 2 | CB042_HUMAN

C2orf42: A Potential Cancer Therapeutic?

C2orf42, also known as chromosome 2 open reading frame 42, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and mental health conditions. Its unique genetic mutation has led to a high degree of interest in its potential as a therapeutic target.

C2orf42 is a gene that is located on chromosome 2, which is one of the two pairs of chromosomes that make up the human genome. It is a region of the genome that contains several hundred genes, and is of particular interest because of its association with a number of diseases.

One of the things that makes C2orf42 such an attractive target is its unique genetic mutation. C2orf42 is a missense mutation, which means that the normal sequence of the gene has been changed to a substitution that results in a change in the way the gene functions. In this case, the substitution results in the loss of a specific amino acid, which is important for the normal function of the protein.

The loss of the amino acid Asp216 is of particular interest, because it is a key residue in a number of proteins that play important roles in various cellular processes. In particular, it is a residue that is involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs.

The fact that C2orf42 is a missense mutation that has been associated with a number of diseases, including cancer, neurodegenerative disorders, and mental health conditions, has led to a high degree of interest in its potential as a therapeutic target. In particular, because of its association with cancer, C2orf42 has been considered as a potential drug target for cancer therapies.

One of the reasons for the interest in C2orf42 as a cancer target is its association with the development of various types of cancer, including breast, ovarian, and prostate cancers. These cancers are among the most common and deadly forms of cancer, and have a high degree of morbidity and mortality. Therefore, targeting C2orf42 as a cancer therapeutic could have a significant impact on treatment outcomes.

Another potential mechanism by which C2orf42 may be targeted as a cancer therapeutic is its role in cell signaling. C2orf42 is a key gene in the TGF-β signaling pathway, which is a critical pathway involved in the regulation of cell growth, differentiation, and survival. In cancer cells, the TGF-β signaling pathway is often disrupted, and this can lead to the development of a range of cancer-related behaviors. Therefore, targeting C2orf42 as a cancer therapeutic could potentially disrupt the TGF-β signaling pathway and inhibit the growth and survival of cancer cells.

In addition to its potential as a cancer therapeutic, C2orf42 has also been considered as a potential biomarker for various mental health conditions, including depression and anxiety. This is because of its association with the regulation of a neurotransmitter called serotonin, which is involved in mood regulation and other aspects of mental health.

The fact that C2orf42 is a gene that has been associated with a number of diseases, including cancer, neurodegenerative disorders, and mental health conditions, has led to a high degree of interest in its potential as a therapeutic target or biomarker. Its unique genetic mutation, as well as its association with the regulation of important cellular processes, make it an attractive candidate for further study as a potential drug or biomarker.

Protein Name: Chromosome 2 Open Reading Frame 42

The "C2orf42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2orf42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets